바이오소재 상처 드레싱 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Biomaterial Wound Dressing Market Summary

The global biomaterial wound dressing market size was estimated at USD 6.63 billion in 2024 and is projected to reach USD 13.02 billion by 2033, growing at a CAGR of 7.92% from 2025 to 2033. This growth is fueled by the rising burden of chronic and hard-to-heal wounds, including diabetic foot ulcers, venous leg ulcers, and pressure injuries, which require advanced, biocompatible materials for faster healing and infection control.

Increasing numbers of surgical procedures worldwide are also boosting demand, as biomaterial-based dressings support improved postoperative recovery and reduce the risk of complications. Technological advancements, such as bioactive polymers, collagen-based scaffolds, and antimicrobial composites, continue to enhance product effectiveness. The shift toward moisture-balanced and regenerative wound therapies further supports market adoption.

The rising prevalence of chronic wounds is a key factor driving the market growth. For instance, as per the data published by Mary Ann Liebert, Inc. in October 2023, chronic wounds are affecting 10.5 million U.S. Medicare beneficiaries. Furthermore, chronic wounds are impacting the quality of life of nearly 2.5% of the total population of the U. S. Similarly, as per the report by the National Library of Medicine (NCBI), in August 2023, about 9.1 to 26.1 million incidences of diabetic foot ulcers occur each year globally. In addition, the rising incidences of burns are expected to propel the demand for collagen wound dressings. For instance, as per a report by Rosenfeld Injury Lawyers LLC, in March 2023, around 450,000 people suffer burn injuries in America each year.

Hip and knee replacement procedures drive the biomaterial wound dressing market because these surgeries involve large incisions and significant tissue disruption, requiring advanced dressings that support faster healing and reduce postoperative complications. As the number of joint replacement surgeries continues to rise, driven by aging populations, osteoarthritis prevalence, obesity, and improved surgical accessibility, the need for effective wound-care solutions grows in parallel. Biomaterial dressings, such as collagen sheets, hydrofiber dressings, and antimicrobial bioactive materials, help manage exudate, prevent surgical site infections, and promote tissue regeneration, all of which are critical for successful recovery after orthopedic procedures. Hospitals and orthopedic centers utilize these advanced dressings to enhance healing outcomes, minimize hospitalization time, and reduce the risk of revisions, making hip and knee replacement surgeries a significant driver of market growth.

In November 2024, the American Joint Replacement Registry (AJRR), a component of the American Academy of Orthopaedic Surgeons (AAOS) Registry Program, announced that its database encompasses over 4 million hip and knee replacement procedures. The 11th Annual Report (2024) highlighted data from more than 3.7 million procedures done between 2012 and 2023.

Burn injuries significantly drive the biomaterial wound dressing market as they require advanced, high-performance dressings that support rapid healing, prevent infection, and minimize scarring. Burns damage multiple layers of skin, making traditional gauze insufficient; this increases the demand for biomaterial-based solutions, such as collagen dressings, hydrogel sheets, bioengineered skin substitutes, and antimicrobial biomaterial films. These products help maintain optimal moisture balance, accelerate tissue regeneration, and reduce pain, which are critical needs in burn care. The rising incidence of thermal burns, electrical burns, chemical burns, and scald injuries, especially in regions with industrial growth and high household accident rates, further accelerates adoption. In addition, specialized burn centers and hospitals prefer biomaterial dressings because they shorten recovery times, lower infection risks, and improve functional and cosmetic outcomes. This growing clinical reliance on advanced mat

erials makes burn injuries a major contributor to overall market growth.

• According to the CDC, burn injuries are a leading cause of accidental death and injury in the U.S., with over 398,000 individuals seeking medical care for burns each year.
• In the UK, 250,000 people suffer burn injuries each year, with 175,000 seeking accident and emergency care and 16,000 requiring hospital admission.
• As per a report published by the World Health Organization (WHO) in October 2023, globally around 180,000 deaths each year are caused by burns.

Global Biomaterial Wound Dressing Market Report Segmentation

This report forecasts revenue growth at the global, regional and country levels, and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biomaterial wound dressing market report on the basis of product, application, end-use and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Natural
  • Alginate
  • Honey
  • Collagen
  • Chitosan
  • Carboxymethyl Cellulose (CMC)
  • Others
• Synthetic
  • Polyurethane
  • Silicone
  • Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Chronic Wounds
  • Diabetic Foot Ulcers
  • Pressure Ulcers
  • Venous Leg Ulcers
  • Other Chronic Wounds
• Acute Wounds
  • Surgical & Traumatic Wounds
  • Burns
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Outpatient Facilities
• Home Healthcare
• Research & Manufacturing
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • KSA
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Details of primary research
  • 1.5.1. Data for primary interviews in North America
  • 1.5.2. Data for primary interviews in Europe
  • 1.5.3. Data for primary interviews in Asia Pacific
  • 1.5.4. Data for primary interviews in Latin America
  • 1.5.5. Data for Primary interviews in MEA
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.7.2. Volume price analysis (Model 2)
    • 1.7.2.1. Approach 2: Volume price analysis
• 1.8. Research Scope and Assumptions
  • 1.8.1. List of Secondary Sources
  • 1.8.2. List of Primary Sources
  • 1.8.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Biomaterial Wound Dressing Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Increasing prevalence of chronic diseases
    • 3.2.1.2. Increasing number of accidents
    • 3.2.1.3. Rising geriatric population
    • 3.2.1.4. Technological advancements in wound dressings
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. Stringent manufacturing policies
  • 3.2.3. Market Opportunities Analysis
    • 3.2.3.1. Expanding healthcare infrastructure
    • 3.2.3.2. Rising interest in antimicrobial and bioactive solutions
  • 3.2.4. Market Challenges Analysis
    • 3.2.4.1. Limited awareness and clinical training
• 3.3. Biomaterial Wound Dressing Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal landscape

Chapter 4. Biomaterial Wound Dressing Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Biomaterial Wound Dressing Market: Product Movement Analysis, USD Million, 2024 & 2033
• 4.3. Global Biomaterial Wound Dressing Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Natural
  • 4.4.1. Natural market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Alginate
    • 4.4.2.1. Alginate market revenue estimates and forecasts, 2021 - 2033 (USD million)
  • 4.4.3. Honey
    • 4.4.3.1. Honey market revenue estimates and forecasts, 2021 - 2033 (USD million)
  • 4.4.4. Collagen
    • 4.4.4.1. Collagen market revenue estimates and forecasts, 2021 - 2033 (USD million)
  • 4.4.5. Chitosan
    • 4.4.5.1. Chitosan market revenue estimates and forecasts, 2021 - 2033 (USD million)
  • 4.4.6. Carboxymethyl cellulose (CMC)
    • 4.4.6.1. Carboxymethyl cellulose (CMC) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.4.7. Others
    • 4.4.7.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD million)
• 4.5. Synthetic
  • 4.5.1. Synthetic market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Polyurethane
    • 4.5.2.1. Polyurethane market revenue estimates and forecasts, 2021 - 2033 (USD million)
  • 4.5.3. Silicone
    • 4.5.3.1. Silicone market revenue estimates and forecasts, 2021 - 2033 (USD million)
  • 4.5.4. Others
    • 4.5.4.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD million)

Chapter 5. Biomaterial Wound Dressing Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Biomaterial Wound Dressing Market: Application Movement Analysis, USD Million, 2024 & 2033
• 5.3. Global Biomaterial Wound Dressing Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Chronic Wounds
  • 5.4.1. Chronic wounds market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.4.2. Diabetic foot ulcer
    • 5.4.2.1. Diabetic foot ulcer market revenue estimates and forecasts, 2021 - 2033 (USD million)
  • 5.4.3. Pressure ulcer
    • 5.4.3.1. Pressure ulcer market revenue estimates and forecasts, 2021 - 2033 (USD million)
  • 5.4.4. Venous leg ulcer
    • 5.4.4.1. Venous leg ulcer market revenue estimates and forecasts, 2021 - 2033 (USD million)
  • 5.4.5. Other chronic wounds
    • 5.4.5.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD million)
• 5.5. Acute Wounds
  • 5.5.1. Acute wounds market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. Surgical & traumatic wounds
    • 5.5.2.1. Surgical & traumatic wounds market revenue estimates and forecasts, 2021 - 2033 (USD million)
  • 5.5.3. Burns
    • 5.5.3.1. Burns market revenue estimates and forecasts, 2021 - 2033 (USD million)

Chapter 6. Biomaterial Wound Dressing Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Biomaterial Wound Dressing Market: End Use Movement Analysis, USD Million, 2024 & 2033
• 6.3. Global Biomaterial Wound Dressing Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.5. Outpatient Facilities
  • 6.5.1. Outpatient facilities market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.6. Home healthcare
  • 6.6.1. Home healthcare market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.7. Research & Manufacturing
  • 6.7.1. Research & manufacturing market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Biomaterial Wound Dressing Market: Regional Estimates & Trend Analysis by Product, Application, & End Use

• 7.1. Regional Dashboard
• 7.2. Market Size and Trend Analysis, 2021 to 2033
• 7.3. North America
  • 7.3.1. North America biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Competitive scenario
    • 7.3.2.3. Regulatory framework
    • 7.3.2.4. Reimbursement scenario
    • 7.3.2.5. U.S. biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Competitive scenario
    • 7.3.3.3. Regulatory framework
    • 7.3.3.4. Reimbursement scenario
    • 7.3.3.5. Canada biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. U.K.
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. Reimbursement scenario
    • 7.4.2.5. U.K. biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Reimbursement scenario
    • 7.4.3.5. Germany biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. Reimbursement scenario
    • 7.4.4.5. France biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Competitive scenario
    • 7.4.5.3. Regulatory framework
    • 7.4.5.4. Reimbursement scenario
    • 7.4.5.5. Italy biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Competitive scenario
    • 7.4.6.3. Regulatory framework
    • 7.4.6.4. Reimbursement scenario
    • 7.4.6.5. Spain biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Competitive scenario
    • 7.4.7.3. Regulatory framework
    • 7.4.7.4. Reimbursement scenario
    • 7.4.7.5. Sweden biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Competitive scenario
    • 7.4.8.3. Regulatory framework
    • 7.4.8.4. Reimbursement scenario
    • 7.4.8.5. Denmark biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key country dynamics
    • 7.4.9.2. Competitive scenario
    • 7.4.9.3. Regulatory framework
    • 7.4.9.4. Reimbursement scenario
    • 7.4.9.5. Norway biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. China biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Japan
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. Japan biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. Reimbursement scenario
    • 7.5.4.5. India biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Reimbursement scenario
    • 7.5.5.5. South Korea biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Australia
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. Reimbursement scenario
    • 7.5.6.5. Australia biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Regulatory framework
    • 7.5.7.4. Reimbursement scenario
    • 7.5.7.5. Thailand biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. Brazil biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Mexico
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. Mexico biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. Argentina
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. Regulatory framework
    • 7.6.4.4. Reimbursement scenario
    • 7.6.4.5. Argentina biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.7. Middle East and Africa
  • 7.7.1. Middle East and Africa biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. Saudi Arabia biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. UAE biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. South Africa
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. South Africa biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Competitive scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Reimbursement scenario
    • 7.7.5.5. Kuwait biomaterial wound dressing market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Market Share Analysis
• 8.4. Company Heat Map Analysis
• 8.5. Strategy Mapping
  • 8.5.1. Expansion
  • 8.5.2. Mergers & Acquisition
  • 8.5.3. Partnerships & Collaborations
  • 8.5.4. New Product Launches
  • 8.5.5. Research And Development
  • 8.5.6. Company Profiles
  • 8.5.7. ConvaTec Group PLC
    • 8.5.7.1. Company overview
    • 8.5.7.2. Financial performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic initiatives
  • 8.5.8. Smith & Nephew PLC
    • 8.5.8.1. Company overview
    • 8.5.8.2. Financial performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic initiatives
  • 8.5.9. Molnlycke Health Care AB
    • 8.5.9.1. Company overview
    • 8.5.9.2. Financial performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic initiatives
  • 8.5.10. B. Braun Melsungen AG
    • 8.5.10.1. Company overview
    • 8.5.10.2. Financial performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic initiatives
  • 8.5.11. 3M
    • 8.5.11.1. Company overview
    • 8.5.11.2. Financial performance
    • 8.5.11.3. Product Benchmarking
    • 8.5.11.4. Strategic initiatives
  • 8.5.12. URGO Medical
    • 8.5.12.1. Company overview
    • 8.5.12.2. Financial performance
    • 8.5.12.3. Product Benchmarking
    • 8.5.12.4. Strategic initiatives
  • 8.5.13. Coloplast Corp.
    • 8.5.13.1. Company overview
    • 8.5.13.2. Financial performance
    • 8.5.13.3. Product Benchmarking
    • 8.5.13.4. Strategic initiatives
  • 8.5.14. Integra LifeSciences
    • 8.5.14.1. Company overview
    • 8.5.14.2. Financial performance
    • 8.5.14.3. Product Benchmarking
    • 8.5.14.4. Strategic initiatives
  • 8.5.15. Medline Industries, Inc.
    • 8.5.15.1. Company overview
    • 8.5.15.2. Financial performance
    • 8.5.15.3. Product Benchmarking
    • 8.5.15.4. Strategic initiatives
  • 8.5.16. Hollister Inc.
    • 8.5.16.1. Company overview
    • 8.5.16.2. Financial performance
    • 8.5.16.3. Product Benchmarking
    • 8.5.16.4. Strategic initiatives
  • 8.5.17. MiMedx Group
    • 8.5.17.1. Company overview
    • 8.5.17.2. Financial performance
    • 8.5.17.3. Product Benchmarking
    • 8.5.17.4. Strategic initiatives
  • 8.5.18. Hartmann Group
    • 8.5.18.1. Company overview
    • 8.5.18.2. Financial performance
    • 8.5.18.3. Product Benchmarking
    • 8.5.18.4. Strategic initiatives
  • 8.5.19. Cardinal Health
    • 8.5.19.1. Company overview
    • 8.5.19.2. Financial performance
    • 8.5.19.3. Product Benchmarking
    • 8.5.19.4. Strategic initiatives
  • 8.5.20. Avita Medical
    • 8.5.20.1. Company overview
    • 8.5.20.2. Financial performance
    • 8.5.20.3. Product Benchmarking
    • 8.5.20.4. Strategic initiatives